Physician profile
Robert Leland
NPI 1447296025
$32,311.79
in general payments reported to CMS, 2019-2025
32 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $1,594 · 2021: $8,341 · 2022: $3,897 · 2023: $14K · 2024: $1,752 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $3,289 · Travel and Lodging: $292 · Education: $24.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,650.00 |
| Food and Beverage | $3,289.31 |
| Travel and Lodging | $291.96 |
| Education | $24.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ossio INC | $13,082.57 | 2022-2024 | |
| Crossroads Extremity Systems, LLC | $4,533.05 | 2021 | |
| Depuy Synthes Sales INC. | $3,923.06 | 2019-2025 | Na, Tfn-Advance, N/A |
| Integra Lifesciences Corporation | $1,915.72 | 2019-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Stryker Corporation | $1,587.44 | 2021-2025 | Prophecy, Axsos, Evolve |
| Arthrex, INC. | $1,205.91 | 2019-2021 | |
| Medtronic, INC. | $1,080.00 | 2021 | |
| Medical Device Business Services, INC. | $900.00 | 2023 | |
| Smith+Nephew, INC. | $823.64 | 2019-2025 | Evos, Conquest Fn, Taylor Spatial Frame |
| Gemini Mountain Medical, LLC | $529.86 | 2021-2024 | |
| Panther Orthopedics, INC. | $500.00 | 2021 | |
| Restor3d, INC. | $459.88 | 2024-2025 | |
| Biotissue Holdings INC. | $280.96 | 2024 | |
| Medline Industries LP | $277.01 | 2021-2024 | |
| Musculoskeletal Transplant Foundation INC. | $217.99 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Solutions INC | $156.10 | 2021-2025 | |
| Orthofix Medical, INC. | $147.49 | 2025 | Fitbone |
| Horizon Therapeutics Plc | $145.28 | 2019-2020 | |
| Gemini Medical LLC | $124.97 | 2021 | |
| Ferring Pharmaceuticals INC. | $60.27 | 2019 | |
| Alliance Medical | $58.78 | 2025 | |
| Radius Health, INC. | $50.83 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $50.29 | 2023-2025 | Exparel |
| Kuros Biosciences USA, INC | $43.62 | 2025 | Magnetos |
| Fidia Pharma USA INC. | $24.55 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $23.79 | 2019 | |
| Organogenesis INC. | $22.93 | 2023 | Puraply |
| Davol INC. | $22.23 | 2023 | Arista Ah Flexitip |
| Maruho Medical, INC. | $18.52 | 2021 | |
| Pacira Therapeutics, INC. | $16.47 | 2019 | |
| Bioventus LLC | $15.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,061.74 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Leland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.